Roche announces FDA approval for COVID-19 test

LabPulse.com staff writers
Jun 17, 2021
2021 02 25 23 48 3444 Covid Virus Dna Molecule 400

Roche announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for its Cobas SARS-CoV-2 nucleic acid test. The test is designed for use on the Cobas Liat system.

Through the authorization, symptomatic and asymptomatic individuals can be tested for COVID-19 at the point of care, with results made available within 20 minutes. The company said the polymerase chain reaction (PCR) test offers broad strain coverage of SARS-CoV-2 variants.

The test will be made available in July.

Latest in PCR
Coronavirus Covid Blue Social
Researchers develop technique for onsite detection of SARS-CoV-2
October 10, 2023
Test Tubes Social
NIH researchers develop PCR assay for easier diagnosis of river blindness
October 9, 2023
Bacteria Blood Sepsis Social
Nonprofit health system adopts Immunexpress test for detecting sepsis
August 23, 2023
Lung Cancer Hotspot Social
ChromaCode starts early-access launch of lung cancer variant test
August 15, 2023
Related Stories
2020 04 14 17 10 6379 Test Tubes Rd Lab 400
Influenza
Roche adds SARS-CoV-2 tests to new Cobas 5800 systems
2020 04 14 17 10 6379 Test Tubes Rd Lab 400
CE mark
Roche launches test on new Cobas 5800 lab system
2019 07 27 00 04 3609 Breast Cancer Cell 400
Breast Cancer
Roche introduces 3 breast cancer pathology AI algorithms
2019 02 13 19 24 5396 Fda Logo V2 400
Emergency Use Authorization
FDA authorizes 11th over-the-counter COVID-19 test
More in PCR
Researchers develop technique for onsite detection of SARS-CoV-2
Researchers have developed a portable laboratory device for rapid onsite detection of SARS-CoV-2 RNA which holds promise for scenarios in which there is no or limited access to testing laboratories.
October 10, 2023
Coronavirus Covid Blue Social
NIH researchers develop PCR assay for easier diagnosis of river blindness
U.S. National Institutes of Health (NIH) researchers have developed a new PCR assay to detect Onchocerca volvulus, the parasite that causes onchocerciasis, or river blindness, and are working to adapt it for easier field diagnosis of the disease.
October 9, 2023
Test Tubes Social
Nonprofit health system adopts Immunexpress test for detecting sepsis
FirstHealth of the Carolinas, a nonprofit health system licensed for four hospitals in North Carolina, will use Immunexpress’ SeptiCyte Rapid test to help differentiate sepsis-positive cases from patients with infection-negative systemic inflammation.
August 23, 2023
Bacteria Blood Sepsis Social
ChromaCode starts early-access launch of lung cancer variant test
The test is designed to address diagnostic problems that prevent patients from undergoing timely cancer biomarker testing and receiving targeted therapies.
August 15, 2023
Lung Cancer Hotspot Social
Studies show Pathnostics UTI test required fewer resources, reduced costs compared to standard testing
In the study, the average one-year costs related to UTIs were $501.85 lower for patients receiving treatment based on the Guidance test than for those receiving treatment based on the traditional culture test.
June 20, 2023
Bladder Urinary 3 D Social
Roche receives WHO prequalification for HPV screening tool
Prequalification helps expand access to the screening tool in countries that rely on the WHO's list of prequalified suppliers in making purchasing and implementation decisions.
June 13, 2023
Lab Woman Dna Social
Eurobio Scientific obtains IVDR CE markings for PCR tests
The CE markings enable the firm to market three of its PCR tests as class C in vitro diagnostic medical devices for the detection of infectious diseases.
May 24, 2023
Business Regulation Graphic Social Resized
A. Menarini launches full automated MDx platform at WorldLab-EuroMedLab
The system, Prime MDx, is an all-in-one, sample-to-result platform designed to allows users to process a variety of sample types through real-time polymerase chain reaction (PCR), the Florence, Italy-based firm said.
May 23, 2023
Artificial Intelligence Ai Social
BioMĂ©rieux receives FDA CLIA waiver for multiplex PCR respiratory panel
In about 15 minutes, the panel detects five of the most common viral causes of upper respiratory tract infections: SARS-CoV-2, influenza A, influenza B, respiratory syncytial virus (RSV), and rhinovirus.
May 11, 2023
Patient Doctor Women Social
Bio-Rad Laboratories Q1 net sales drop 3%; firm lowers full-year guidance
Bio-Rad shares were down on Friday, a day after the firm updated its financial outlook for full-year 2023; it anticipates non-GAAP currency-neutral revenue growth of approximately 4.5% compared to its previous estimate of 6% to 7%.
May 5, 2023
Business Financial Results Social
Qiagen launching syndromic molecular diagnostic system with respiratory panel in Japan
Qiagen said Monday that its QIAstat-Dx syndromic testing system is expected to be available soon in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a patient sample.
April 24, 2023
Women Laboratory Social
Curative spins off Sensible Diagnostics to commercialize point-of-care PCR platform
The spin-off is utilizing the experience Curative has gained with its diagnostics business during the pandemic, having run more than two million molecular point-of-care COVID-19 tests.
April 24, 2023
Blood Test Samples Lab Social
Page 1 of 22
Next Page